Molecular Formula | C33H33N9O2 |
Molar Mass | 587.67 |
Density | 1.353±0.06(20.0000℃) |
Melting Point | >214°C (dec.) |
Boling Point | 857.3±65.0 °C(Predicted) |
Solubility | DMSO (Slightly) |
Appearance | Solid |
Color | Pale Yellow |
pKa | 12.05±0.40(Predicted) |
Storage Condition | Refrigerator |
In vitro study | SCH772984 is a novel, selective, ATP-competitive ERK1/2 inhibitor. SCH772984 inhibited the phosphorylation of the ERK substrate p90 ribosomal S6 kinase (T359/S363 phosphorylation-RSK) in a dose-dependent manner. SCH772984 also inhibits phosphorylation of residues in the activation loop of ERK itself. SCH772984 inhibited approximately 88% and 49% of the BRAF-mutant or RAS-mutant tumor cell lines, respectively, with EC50 values <500 nM. |
In vivo study | SCH772984 treated the xenograft model at a tolerated dose to induce tumor regression. Sch 772984 acts on a model of anti-BRAF or MEK inhibitors, effectively inhibiting MAPK signaling and cell proliferation. |
HS Code | 29339900 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.702 ml | 8.508 ml | 17.016 ml |
5 mM | 0.34 ml | 1.702 ml | 3.403 ml |
10 mM | 0.17 ml | 0.851 ml | 1.702 ml |
5 mM | 0.034 ml | 0.17 ml | 0.34 ml |
biological activity | SCH772984 is a novel specific inhibitor of ERK1/2, the IC50 in the cell-free assay is 4 nM and 1 nM, respectively, and has powerful efficacy against cancer cells containing RAS or BRAF mutations. |
Target | Value |
ERK2 (Cell-free assay) | 1 nM |
ERK1 (Cell-free assay) | 4 nM |